The Pentecost Foundation--established in honor of teacher-turned-entrepreneur Mark Pentecost--recently made a $3 million gift to Moffitt Cancer Center to support the research at the forefront of curing his multiple myeloma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has approved Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of people with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
FDA has published a draft guidance on “class labeling” of diagnostic tests for oncology therapeutic products, where scientifically appropriate.
FDA has published a document outlining it approach to interpretation of real-world evidence.
Kite, a Gilead company, announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of two years after a single infusion of Yescarta (median follow up of 27.1 months), 39 percent of patients were in an ongoing response.
Kite, a Gilead company, announced updated results from ZUMA-3, a single-arm phase I/II study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed or refractory acute lymphoblastic leukemia.
An interim analysis of a large phase III clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreated chronic lymphocytic leukemia.
The Janssen Pharmaceutical Companies of Johnson & Johnson reported updated results from Legend Biotech Inc.'s LEGEND-2 phase I/II open-label study, which evaluated the investigational chimeric antigen receptor T-cell therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory multiple myeloma.
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.
